长春高新：口服小分子生长激素促分泌药物GS3-007a干混悬剂临床试验申请获批

Core Viewpoint - Changchun High-tech (000661) announced the approval of the clinical trial application for its subsidiary Jinsai Pharmaceutical's GS3-007a dry suspension, a novel oral growth hormone secretagogue aimed at treating pediatric growth hormone deficiency (PGHD) [1] Group 1: Product Development - GS3-007a is an innovative oral medication developed by Jinsai Pharmaceutical, classified as a Class 1 chemical drug [1] - The product is intended for the treatment of PGHD, a common endocrine disorder in pediatrics that leads to short stature and delayed development [1] - Currently, there are no similar products available in the domestic market for PGHD treatment [1] Group 2: Market Context - PGHD has an incidence rate of approximately 1 in 8,600 in China, with the most common cause being idiopathic growth hormone deficiency [1] - Existing treatments for GHD include daily injections of recombinant human growth hormone (rhGH) and weekly injections of long-acting growth hormone (LAGH) [1] - GS3-007a offers a new treatment option through daily oral administration, providing more choices for children in need of growth promotion [1]